Johnson & Johnson (JNJ) announced last night its decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder “due to insufficient efficacy in the target patient population.” J&J said, “The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified. Based on the potential for this mechanism, the Company will explore future development opportunities for aticaprant in other areas of high unmet need. Full analyses from the VENTURA development program are underway and will be shared at a future medical meeting.” Both Stifel and Guggenheim downgraded Neumora Therapeutics (NMRA) following Johnson & Johnson’s decision, citing less conviction in Neumora’s lead asset navacaprant. Shares of Neumora are down 11% to $1.35 in premarket trading while Johnson & Johnson is down 33c to $165.50.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Neumora Therapeutics downgraded to Neutral from Buy at Guggenheim
- Neumora Therapeutics downgraded to Hold from Buy at Stifel
- Amgen price target raised to $294 from $275 at BofA
- Johnson & Johnson price target raised to $171 from $159 at BofA
- HHS increasing scrutiny of vaccines under RFK Jr., WSJ reports
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue